We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-3.57%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$482M
AUM Growth
-$20.7M
Cap. Flow
+$53M
Cap. Flow %
10.99%
Top 10 Hldgs %
87.43%
Holding
20
New
4
Increased
2
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$17.8M
2
CRVS icon
Corvus Pharmaceuticals
CRVS
+$11.1M
3
ALT icon
Altimmune
ALT
+$9.93M
4
ATYR
aTyr Pharma
ATYR
+$6.66M
5
CYPH
Cypherpunk Technologies Inc
CYPH
+$4.7M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 96.14%
2 Financials 2.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
1
Heron Therapeutics
HRTX
$86.3M
$84.5M 17.55%
7,907,087
– –
RCKT icon
2
Rocket Pharmaceuticals
RCKT
$348M
$75.7M 15.71%
2,531,800
– –
ANAB icon
3
AnaptysBio
ANAB
$1.6B
$71.3M 14.8%
2,628,678
– –
ODT
4
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$45.1M 9.37%
15,514,566
– –
LJPC
5
DELISTED
La Jolla Pharmaceutical Company
LJPC
$40.1M 8.32%
10,049,224
– –
APVO icon
6
Aptevo Therapeutics
APVO
$5.47M
$27.2M 5.64%
3
– –
ITOS
7
DELISTED
iTeos Therapeutics
ITOS
$24.3M 5.05%
900,000
+680,604
+310% +$17.8M
CRVS icon
8
Corvus Pharmaceuticals
CRVS
$1.1B
$18.1M 3.77%
+3,749,379
New +$11.1M
ALT icon
9
Altimmune
ALT
$539M
$18.1M 3.76%
1,600,000
+816,593
+104% +$9.93M
VINC
10
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$16.7M 3.46%
51,532
– –
CHRS icon
11
Coherus Oncology
CHRS
$217M
$10.4M 2.17%
650,000
– –
ATYR
12
aTyr Pharma
ATYR
$46.4M
$10.1M 2.1%
+1,113,453
New +$6.66M
CYPH
13
Cypherpunk Technologies Inc
CYPH
$66.2M
$10M 2.08%
+250,000
New +$4.7M
CCXI
14
DELISTED
ChemoCentryx, Inc.
CCXI
$8.55M 1.78%
500,000
– –
TNGX icon
15
Tango Therapeutics
TNGX
$4.34B
$6.06M 1.26%
468,750
– –
RVPH
16
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$4.88M 1.01%
60,000
– –
EQ icon
17
Equillium
EQ
$157M
$4.09M 0.85%
600,000
– –
RLMD icon
18
Relmada Therapeutics
RLMD
$544M
$2.62M 0.54%
100,000
– –
NXTC icon
19
NextCure
NXTC
$17.3M
$2.02M 0.42%
25,000
– –
ASLN
20
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.74M 0.36%
+24,383
New +$2.77M

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $1.98B AUM 1.62% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return

Tang Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Tang Capital Management held 20 positions worth $482M, down 4.1% from $502M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Tang Capital Management deployed $53M of net new capital in Q3 2021, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was Corvus Pharmaceuticals: 3,749,379 shares worth $18.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier, followed by Financials.

  • Tang Capital Management's largest Q3 2021 buy was Corvus Pharmaceuticals: 3,749,379 shares worth $18.1M.
  • Tang Capital Management added most to iTeos Therapeutics in Q3 2021, an estimated $17.8M increase.
  • Tang Capital Management's ten largest holdings make up 87% of its $482M portfolio in Q3 2021.
  • Tang Capital Management opened 4 new positions and closed 0 in Q3 2021.
  • Tang Capital Management's portfolio value fell 4.1% quarter-over-quarter to $482M.

Based on Tang Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.